Sorry, you need to enable JavaScript to visit this website.

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)

AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety
Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Category & Conditions: Cancer
Medicine: Xtandi (enzalutamide) Identifier (NCT): NCT00974311
Protocol ID: C3431010
Open Plain Language Summary Result: Click here